- Trials with a EudraCT protocol (139)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
139 result(s) found for: CGM.
Displaying page 3 of 7.
EudraCT Number: 2017-002374-39 | Sponsor Protocol Number: I8B-MC-ITSI | Start Date*: 2017-12-27 | |||||||||||
Sponsor Name:Lilly S.A. | |||||||||||||
Full Title: Protocol I8B-MC-ITSI A Prospective, Randomized, Double-Blind, Crossover Comparison Evaluating Compatibility and Safety of LY900014 and Insulin Lispro with an External Continuous Subcutaneous Insuli... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001942-24 | Sponsor Protocol Number: HypoDeg | Start Date*: 2014-10-23 | |||||||||||
Sponsor Name:Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology | |||||||||||||
Full Title: The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in subjects with type 1 diabetes and high risk of nocturnal severe hypoglycaemia | |||||||||||||
Medical condition: Sypmtomatic nocturnal hypoglycaemia in subjects with type 1 diabetes and high risk of nocturnal severe hypoglyceamia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000393-29 | Sponsor Protocol Number: 69HCL18_0047 | Start Date*: 2018-07-04 | ||||||||||||||||
Sponsor Name:Hospices Civils de Lyon | ||||||||||||||||||
Full Title: Dulaglutide And Insulin MicrosecretiON in type I Diabetes - DIAMOND | ||||||||||||||||||
Medical condition: Adult patients with Type 1 Diabètes (T1D)> 4years | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005499-41 | Sponsor Protocol Number: CLAF237A2411 | Start Date*: 2012-12-05 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A double blind, double dummy, randomised, multi-centre study to assess the tolerability and efficacy profile of vildagliptin compared to gliclazide as dual therapy with metformin in Muslim patients... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005353-82 | Sponsor Protocol Number: LPS17375 | Start Date*: 2022-05-09 | |||||||||||
Sponsor Name:Sanofi-Aventis S.A | |||||||||||||
Full Title: Prospective study to assess with Continuous Glucose Monitoring (CGM) the efficacy and safety of switching to insulin glargine 300 U/ml from insulin glargine 100 U/ml in Type 2 Diabetes (T2DM) patie... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000743-68 | Sponsor Protocol Number: LDX0122 | Start Date*: 2022-12-13 | |||||||||||
Sponsor Name:DOMPé FARMACEUTICI S.P.A. | |||||||||||||
Full Title: A phase II randomized, placebo-controlled, double-blinded, 2-parallel arm, clinical trial evaluating Ladarixin 400 mg twice a day as adjunctive therapy to improve glycemic control in overweight ins... | |||||||||||||
Medical condition: overweight insulin-resistant patients with type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003032-13 | Sponsor Protocol Number: DF-07 | Start Date*: 2016-09-15 | |||||||||||
Sponsor Name:A.O.U. Università degli Studi della Campania "Luigi Vanvitelli" | |||||||||||||
Full Title: A 16 week PILOT Study to determine the Frequency of Suphonylurea-Associated Hypoglycaemia in older moderately frail patients with type 2 diabetes mellitus poorly controlled on metformin: an open la... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005878-25 | Sponsor Protocol Number: I8H-MC-BDCV | Start Date*: 2022-10-24 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults with Type 2 Dia... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004944-39 | Sponsor Protocol Number: NPJ005-DM2-0522 | Start Date*: 2018-04-27 | |||||||||||
Sponsor Name:neopharma Japan Co., Ltd | |||||||||||||
Full Title: A 24 Week, Phase IIa, Double blind, Randomized, Parallel Group, Placebo-controlled, Proof of Concept Study to Assess the Efficacy and Safety of Two Doses of 5 Aminolevulinic Acid Co-administered wi... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) HU (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004546-15 | Sponsor Protocol Number: ZP4207-17106 | Start Date*: 2018-08-24 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism | |||||||||||||
Medical condition: Children with congenital hyperinsulinism | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005153-39 | Sponsor Protocol Number: LX4211.1-310-T1DM | Start Date*: 2015-04-28 | |||||||||||
Sponsor Name:Lexicon Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients with Typ... | |||||||||||||
Medical condition: Type 1 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) AT (Completed) ES (Completed) LT (Completed) DE (Completed) GB (Completed) HU (Completed) BE (Completed) SE (Completed) NL (Completed) PL (Completed) BG (Completed) RO (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005256-26 | Sponsor Protocol Number: 1245.72 | Start Date*: 2015-12-23 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 2... | |||||||||||||
Medical condition: Patients with confirmed, insulin-dependent type 1 diabetes mellitus for at least 1 year | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) GB (Completed) FI (Completed) IE (Completed) LV (Completed) NL (Completed) HU (Completed) PT (Completed) GR (Completed) FR (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001150-26 | Sponsor Protocol Number: Protokol(Lira-1)v8 | Start Date*: 2012-05-21 | |||||||||||
Sponsor Name:Steno Diabetes Center | |||||||||||||
Full Title: Liraglutide in type 1 diabetes. A randomised, double-blind, placebo controlled study of the effect of liraglutide as an additional treatment to insulin on HbA1c, body weight and hypoglycaemia in po... | |||||||||||||
Medical condition: Primary objective:To investigate the effect of liraglutide 1.8 mg once daily compared to placebo for 24 weeks on change in HbA1c in patients with type 1 diabetes as an add-on therapy to insulin. S... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002259-14 | Sponsor Protocol Number: TRG12-05 | Start Date*: 2013-11-27 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: The effect of lixisenatide in type 1 diabetes | |||||||||||||
Medical condition: Type 1 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002374-27 | Sponsor Protocol Number: NN1436-4625 | Start Date*: 2021-04-01 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of once weekly insulin icodec compared to once daily insulin degludec 100 units/mL, both in combination with insulin aspart, in adults with type 1 diabetes. A 26-week, randomis... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000397-19 | Sponsor Protocol Number: Ctrl-DM2 | Start Date*: 2014-09-09 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Effects of Combined Treatment of Surgery and Liraglutide on Glycemic Variability and Control in type 2 Diabetes Mellitus: The Ctrl-DM2 Study | ||
Medical condition: type 2 diabetes with morbid obesity | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006251-46 | Sponsor Protocol Number: V4ByIns | Start Date*: Information not available in EudraCT |
Sponsor Name:Institute of Diabetes “Gerhardt Katsch” | ||
Full Title: Prediction of the efficacy of exenatide treatment in suboptimally controlled type 2 diabetic patients by “Metabolic Fingerprint” and evidence-based KADIS® decision support: a clinical pilot trial | ||
Medical condition: the trial will be performed in a total of 58 male and female patients with type 2 diabetes who will be assigned to two groups, receiving either exenatide or insulin glargine | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004547-21 | Sponsor Protocol Number: ZP4207-17109 | Start Date*: 2018-08-24 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism | |||||||||||||
Medical condition: Children with congenital hyperinsulinism | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000454-10 | Sponsor Protocol Number: NN1436-4478 | Start Date*: 2021-02-09 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 26-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin degludec, both with or without non-insulin anti-diabetic drugs, in subjects with type 2 diabetes... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000474-16 | Sponsor Protocol Number: NN1436-4480 | Start Date*: 2020-11-19 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 26-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with bolus insulin with or without non-insulin anti-d... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
